<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10507769</article-id><article-id pub-id-type="pmc">2362932</article-id><article-id pub-id-type="pii">6690714</article-id><article-id pub-id-type="doi">10.1038/sj.bjc.6690714</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Viens</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Palangi&#x000e9;</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Janvier</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Fabbro</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Roch&#x000e9;</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Delozier</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Labat</surname><given-names>J P</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Linassier</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff8">8</xref></contrib><contrib contrib-type="author"><name><surname>Audhuy</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff9">9</xref></contrib><contrib contrib-type="author"><name><surname>Feuilhade</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff10">10</xref></contrib><contrib contrib-type="author"><name><surname>Costa</surname><given-names>B</given-names></name><xref ref-type="aff" rid="aff11">11</xref></contrib><contrib contrib-type="author"><name><surname>Delva</surname><given-names>R</given-names></name><xref ref-type="aff" rid="aff12">12</xref></contrib><contrib contrib-type="author"><name><surname>Cure</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff13">13</xref></contrib><contrib contrib-type="author"><name><surname>Rousseau</surname><given-names>F</given-names></name><xref ref-type="aff" rid="aff14">14</xref></contrib><contrib contrib-type="author"><name><surname>Guillot</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff15">15</xref></contrib><contrib contrib-type="author"><name><surname>Mousseau</surname><given-names>M</given-names></name><xref ref-type="aff" rid="aff16">16</xref></contrib><contrib contrib-type="author"><name><surname>Ferrero</surname><given-names>J M</given-names></name><xref ref-type="aff" rid="aff17">17</xref></contrib><contrib contrib-type="author"><name><surname>Bardou</surname><given-names>V J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Jacquemier</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pouillart</surname><given-names>P</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Institut Paoli Calmettes, 232 Blvd Sainte Marguerite, Marseille, Cedex 09, 13273, France</aff><aff id="aff2"><label>2</label>Institut Curie, Paris, France</aff><aff id="aff3"><label>3</label>Centre Ren&#x000e9; Huguenin, Saint-Cloud, France</aff><aff id="aff4"><label>4</label>Centre Val d'Aurelle, Montpellier, France</aff><aff id="aff5"><label>5</label>Centre Claudius Regaud, Toulouse C, France</aff><aff id="aff6"><label>6</label>Centre Fran&#x000e7;ois Baclesse, Caen, France</aff><aff id="aff7"><label>7</label>CHU A Morvan, Brest, France</aff><aff id="aff8"><label>8</label>H&#x000f4;pital Bretonneau, Tours, France</aff><aff id="aff9"><label>9</label>H&#x000f4;pital Pasteur, Colmar, France</aff><aff id="aff10"><label>10</label>CHU Henri Mondor, Cr&#x000e9;teil, France</aff><aff id="aff11"><label>11</label>Institut Jean Godinot, Reims, France</aff><aff id="aff12"><label>12</label>Centre Paul Papin, Angers, France</aff><aff id="aff13"><label>13</label>n, Centre Jean Perri, Clermont-Ferrand, France</aff><aff id="aff14"><label>14</label>Centre Ren&#x000e9; Dubos, Pontoise, France</aff><aff id="aff15"><label>15</label>H&#x000f4;pital Nord, Saint-Etienne, France</aff><aff id="aff16"><label>16</label>CHU A Michallon, Grenoble, France</aff><aff id="aff17"><label>17</label>Centre Antoine Lacassagn, Nice, France</aff><pub-date pub-type="ppub"><month>10</month><year>1999</year></pub-date><volume>81</volume><issue>3</issue><fpage>449</fpage><lpage>456</lpage><history><date date-type="received"><day>24</day><month>02</month><year>1998</year></date><date date-type="rev-recd"><day>25</day><month>03</month><year>1999</year></date><date date-type="accepted"><day>12</day><month>04</month><year>1999</year></date></history><copyright-statement>Copyright 1999, Cancer Research Campaign</copyright-statement><copyright-year>1999</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>Despite the generalization of induction chemotherapy and a better outcome for chemosensitive diseases, the prognosis of inflammatory breast cancer (IBC) is still poor. In this work, we evaluate response and toxicity of high-dose sequential chemotherapy with repeated blood stem cell (BSC) transplantation administered as initial treatment in 100 women with non-metastatic IBC. Ninety-five patients (five patients were evaluated as non-eligible) of median age 46 years (range 26&#x02013;56) received four cycles of chemotherapy associating: cyclophosphamide (C) 6 g m<sup>&#x02212;2</sup> &#x02013; doxorubicin (D) 75 mg m<sup>&#x02212;2</sup> cycle 1, C: 3 g m<sup>&#x02212;2</sup> &#x02013; D: 75 mg m<sup>&#x02212;2</sup> cycle 2, C: 3 g m<sup>&#x02212;2</sup> &#x02013; D: 75 mg m<sup>&#x02212;2</sup> &#x02013; 5 FU 2500 mg m<sup>&#x02212;2</sup> cycle 3 and 4. BSC were collected after cycle 1 or 2 and reinfused after cycle 3 and 4. rG-CSF was administered after the four cycles. Mastectomy and radiotherapy were planned after chemotherapy completion. Pathological response was considered as the first end point of this trial. A total of 366 cycles of chemotherapy were administered. Eighty-seven patients completed the four cycles and relative dose intensity was respectively 0.97 (range 0.4&#x02013;1.04) and 0.96 (range 0.25&#x02013;1.05) for C and D. Main toxicity was haematological with febrile neutropenia ranging from 26&#x00025; to 51&#x00025; of cycles; one death occurred during aplasia. Clinical response rate was 90&#x00025; &#x000b1; 6&#x00025;. Eighty-six patients underwent mastectomy in a median of 3.5 months (range 3&#x02013;9) after the first cycle of chemotherapy; pathological complete response rate in breast was 32&#x00025; &#x000b1; 10&#x00025;. All patients were eligible to receive additional radiotherapy. High-dose chemotherapy with repeated BSC transplantation is feasible with acceptable toxicity in IBC. Pathological response rate is encouraging but has to be confirmed by final outcome. &#x000a9; 1999 Cancer Research Campaign</p></abstract><kwd-group><kwd>inflammatory breast cancer</kwd><kwd>high-dose sequential chemotherapy</kwd></kwd-group></article-meta></front></article>


